Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by themagicboxon Jul 16, 2020 11:57am
242 Views
Post# 31276277

RE:RE:can we just break the $0.40 mark

RE:RE:can we just break the $0.40 markThere is always penny flippers. I do that all the time. And I always recommend people take profits when they can. Likely we will see sp rise after the CEO/SH letter, esp if it lays out the dates for the upcoming catalysts. 

People didnt believe me when I said it was over valued prior to ph2 results at .76 and would have never thought it would tank back under $0.40. So always take profits if possible.

Given that it has been significantly de-risked, it value should be well above a $1. I got the bought deal and I agree with the above sentiment about future value of cash. 

 
Forestview wrote: This is a good summary of how I feel, except I reupped in the $0.50s.  I don't understand how it continues to move $0.005 then down $0.01.  It's beyond frustrating.  I still believe in the product but this is painful.   


Bullboard Posts